BC Innovations | Oct 20, 2016
Distillery Therapeutics

Cancer

INDICATION: Cancer Cell culture and mouse studies suggesting inhibiting SET could help treat p53 -mutant cancers. In a human p53-mutant bone cancer cell line, siRNA targeting SET decreased proliferation compared with scrambled siRNA. In a...
BioCentury | Jun 23, 2014
Emerging Company Profile

Dual: Multi-pronged attack

Dual Therapeutics LLC is developing first-in-class oral small molecules that directly activate protein phosphatase 2 to disrupt multiple cancer pathways simultaneously. By restoring the phosphatase's activity to normal levels, the approach could treat prostate cancers...
BC Innovations | Oct 3, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic myelogenous leukemia (CML) Protein phosphatase 2 (PPP2CA; PP2A) Studies in patient samples and mice suggest Gilenya fingolimod and nonimmunosuppressive derivatives could help eradicate leukemic...
BioCentury | Jul 23, 2012
Emerging Company Profile

Oncotide: SETting up phosphatases

Oncotide Pharmaceuticals Inc. believes it has found a way to deactivate the phosphorylation that is a driver of oncogenic signaling, an approach that could provide an alternative or add-on to kinase inhibitors for blocking growth...
BC Innovations | Sep 1, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL); non-Hodgkin's lymphoma (NHL) SET nuclear oncogene (SET) Mouse and patient studies suggest inhibiting SET could help treat B cell CLL and...
BC Week In Review | Apr 11, 2011
Company News

Cognosci, Oncotide deal

Cognosci spun-out newco Oncotide to discover and develop protein phosphatase modulators to treat cancer. Cognosci granted Oncotide an exclusive license for IP covering its cancer pipeline, and provided undisclosed seed financing. Oncotide's lead product, OP449...
Items per page:
1 - 6 of 6
BC Innovations | Oct 20, 2016
Distillery Therapeutics

Cancer

INDICATION: Cancer Cell culture and mouse studies suggesting inhibiting SET could help treat p53 -mutant cancers. In a human p53-mutant bone cancer cell line, siRNA targeting SET decreased proliferation compared with scrambled siRNA. In a...
BioCentury | Jun 23, 2014
Emerging Company Profile

Dual: Multi-pronged attack

Dual Therapeutics LLC is developing first-in-class oral small molecules that directly activate protein phosphatase 2 to disrupt multiple cancer pathways simultaneously. By restoring the phosphatase's activity to normal levels, the approach could treat prostate cancers...
BC Innovations | Oct 3, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic myelogenous leukemia (CML) Protein phosphatase 2 (PPP2CA; PP2A) Studies in patient samples and mice suggest Gilenya fingolimod and nonimmunosuppressive derivatives could help eradicate leukemic...
BioCentury | Jul 23, 2012
Emerging Company Profile

Oncotide: SETting up phosphatases

Oncotide Pharmaceuticals Inc. believes it has found a way to deactivate the phosphorylation that is a driver of oncogenic signaling, an approach that could provide an alternative or add-on to kinase inhibitors for blocking growth...
BC Innovations | Sep 1, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL); non-Hodgkin's lymphoma (NHL) SET nuclear oncogene (SET) Mouse and patient studies suggest inhibiting SET could help treat B cell CLL and...
BC Week In Review | Apr 11, 2011
Company News

Cognosci, Oncotide deal

Cognosci spun-out newco Oncotide to discover and develop protein phosphatase modulators to treat cancer. Cognosci granted Oncotide an exclusive license for IP covering its cancer pipeline, and provided undisclosed seed financing. Oncotide's lead product, OP449...
Items per page:
1 - 6 of 6